IRCT20210519051345N43RecruitingUnknown
Fasted-state in vivo bioequivalence study of Gliclazide 60 mg sustained release tablet manufactured by AaniDarman compared with innovator product
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 59 years (—)
- Sex
- All
Inclusion Criteria
- •General Health (in terms of Liver, Heart and Kidney)
- •Age (18-59 years)
Exclusion Criteria
- •History of cardiovascular disease, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
Investigators
Similar Trials
Not yet recruiting
Unknown
Bioequivalence study of Gliclazide 60 mg tabletIRCT20210519051345N63Tabriz University of Medical Sciences24
Not yet recruiting
Unknown
In vivo Bioequivalence study of Levodopa/benserazide tabletsIRCT20220211053992N32Tabriz University of Medical Sciences24
Not yet recruiting
Unknown
In vivo Bioequivalence study of Levodopa/benserazide tabletsIRCT20220211053992N34Tabriz University of Medical Sciences24
Not yet recruiting
Not Applicable
Investigating the in vivo bioequivalence of Celecoxib 100 mg tabletIRCT20210519051345N15Tabriz University of Medical Sciences24
Recruiting
Unknown
Investigating the in vivo bioequivalence of Sildenafil 100 mgIn the present study, the products will be administered to healthy volunteers..IRCT20210519051345N28Tabriz University of Medical Sciences24